134 results about "Dose" patented technology

Systems, devices and methods are provided for determining a medication dose for a patient or user. The dose determination can account for recent and / or historical analyte levels of the patient or user. The dose determination can also take into account other information about the patient or user, such as physiological information, dietary information, activity, and / or behavior. Many different dose determination embodiments are set forth, pertaining to a wide array of different aspects of the system or environment in which the embodiments can be implemented.

The invention belongs to the technical field of preparation of probiotics, and provides a bacterial strain with anti-allergic and immunity-improving effects and application of the bacterial strain. According to the method, a three-layer physical self-assembly structure is adopted, and polysaccharide-polyphenol layer-by-layer self-assembly coating treatment, lipid insertion layer treatment and calcium ion crosslinking protection coating treatment are sequentially carried out. And mannan oligosaccharide MOS and / or galactooligosaccharide GOS are / is mixed in the chitosan layer in a ratio of 0.05-0.15% w / v, and the surface sugar ligand density reaches 4-8 [mu] g per 10 CFU. The coating is constructed under the condition that the pH value is 5.4-5.8; the thickness of the lipid layer is 20-80 nm when the pH value is 5.6-6.2; the cross-linked layer is treated at the pH of 6.0-6.5, so that the gastric acid environment is stable for 2 hours, and the gastric acid is controllably released in intestinal juice for 2-4 hours. The prepared strain has the total thickness of 220-900 nm, the outermost layer coverage rate is larger than or equal to 85%, the gastric juice survival rate is remarkably improved, the strain can be prepared into an oral preparation to be used for preventing and relieving allergic diseases, the viable count of each dose is 1 * 10 <-1 > * 10 <-1 > CFU, and the process is mild and suitable for industrial production.

The invention discloses a method and system for analyzing a bacterium-drug interaction panoramic dynamic mechanism by using a causal enlightenment hypergraph neural network, and electronic equipment, and belongs to the technical field of artificial intelligence and biomedical informatics. The method comprises the following steps: constructing a disease / syndrome / disease-bacterium / microorganism / metabolite-prescription / drug / component interlocking hypergraph; analyzing a bacteria-drug interaction dynamic mechanism based on a dynamic hypergraph network algorithm; optimizing the hypergraph neural network based on the prescription compatibility rule and the traditional Chinese medicine dosage; and predicting the microbial marker based on the causal enlightenment hypergraph neural network. According to the method, a multi-entity high-order relation is captured through an interlocking hypergraph structure, a time sliding window and an attenuation mechanism are introduced to analyze dynamic evolution, the traditional Chinese medicine dosage is used as an attention priori optimization network, and causal reasoning is achieved through alternate optimization of an intervention discovery and response prediction module. In a public data set test, the performance evaluation index is obviously superior to that in the prior art, and the problem of analyzing the panoramic dynamic mechanism of the bacterium-drug interaction is effectively solved.

A processor-implemented method comprises obtaining measured glucose values of a person, fitting a physiological model to a portion of the measured glucose values within a time window after a start of a meal to determine meal-specific values of parameters of the physiological model that characterizes the person's glycemic response to the meal, estimating an amount of residual glucose or residual carbohydrate of the meal that would not be counteracted by insulin already delivered to the person using the physiological model and the meal-specific values of the parameters of the physiological model, and determining a dose of a correction bolus to be delivered to the person based on the amount of residual glucose or residual carbohydrate of the meal.

A personalized supplement formulation system integrates biological data, structured qualitative feedback, and machine learning algorithms to generate individualized nutritional protocols. The system receives biological inputs such as genetic single nucleotide polymorphism (SNP) data, blood biomarkers (e.g., ferritin, vitamin D, B12), lipid profiles, and urinary metabolites. A digital user profile is created by organizing these inputs and calculating derived indices relevant to supplementation. Structured qualitative feedback, including dietary restrictions, perceived wellness, and training goals, is normalized and processed alongside the biological data. A trained machine learning engine analyzes combined inputs to output a tailored supplement formulation specifying ingredient selection, dosage, delivery format, and timing. Instructions are transmitted to a manufacturing system capable of producing the custom formulation. The system supports periodic re-evaluation and iteration based on new biological samples or user-reported feedback, enabling dynamic personalization over time and improving efficacy, compliance, and outcome tracking in athletic and wellness domains.

The application discloses a point application traditional Chinese medicine composition with an effect of treating irritable bowel syndrome, a point application plaster and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The application provides a point application traditional Chinese medicine composition and a point application plaster. The traditional Chinese medicine composition comprises the following components: psoralea, radix codonopsis, dried zedoary, fried atractylodes, mace, schisandra chinensis and evodia. The composition is prepared according to the principle of less medicine and special function and treatment of disease and seeking the origin. The core tonifying medicine, psoralea, dried zedoary and radix codonopsis, has a prominent dosage proportion and remarkable effects of warming the spleen and kidney yang and invigorating the spleen and replenishing qi. The application finds through clinical research that the clinical total effective rate of the test group is 76.7%, the curative effect is accurate and better than that of a placebo, the IBS-SSS score, the TCM syndrome score and the stool character score of IBS patients can be reduced, the symptoms of the patients are improved, and the composition can effectively treat IBS.

The invention relates to the technical field of information, and discloses a method for predicting the optimal ratio of arginine to lysine in daily ration of lactating sows, and the method comprises the following steps: 1, obtaining historical production data and feed formula data; 2, performing data preprocessing on the historical production data and the feed formula data to obtain historical feature vectors and formula sample data; 3, selecting a preset model with the best performance as a prediction model according to the performance indexes; 4, inputting the to-be-detected feature vector and the crude protein content into the prediction model, and outputting a proportion prediction value of arginine and lysine by the prediction model; 5, performing a field dose response test and acquiring field data; and step 6, inputting the field data into the prediction model, detecting whether data drift occurs in the field data, performing incremental learning when no significant drift occurs in the field data, and performing full-amount learning when significant drift occurs in the field data. The invention further discloses a device for predicting the optimal arginine and lysine ratio of the daily ration of the lactating sows.

To provide a method for treating a proteinuric kidney disease.SOLUTION: There is provided a method comprising administering a predetermined daily dosage of effective amounts of voclosporin over a projected treatment period of at least 24 weeks. The method further comprises: (a) assessing an estimated Glomerular Filtration Rate (eGFR) of a subject at at least a first time point and a second time point on different days within the treatment period; and (b) (i) when the eGFR of the subject decreases by more than a target % to below a predetermined value between the first and second time points, reducing the daily dosage by units of 7.9 mg BID or discontinuing the administration of voclosporin to the subject; (ii) when the eGFR of the subject decreases by less than the target % between the first and second time points, continuing to administer the same predetermined daily dosage of voclosporin to the subject.SELECTED DRAWING: Figure 1

Methods and related compositions using Dichrostachys glomerata to provide a variety of health and wellness benefits in a mammal. More specifically, methods and compositions using Dichrostachys glomerata to reduce anxiety, food cravings, stress and improve mood, physical health, mental health, energy and happiness and improve other quality of life factors in one or more mammals, are provided. In one embodiment, a composition for improving mood in a mammal is provided, wherein the composition comprises an effective amount of Dichrostachys glomerata fruit pods provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

The present disclosure provides a method of administering a low dose soluble protein to a subject in need thereof, wherein the method comprises (a) adding an intravenous solution stabilizer ("IVSS") to an isotonic aqueous solution in a container to form a pretreated container, (b) adding an amount from a protein stock solution to the pretreated container of step (a) to form a low dose protein solution, and (c) administering the low dose protein solution of step (b) to the subject. Optionally, the dose of the soluble protein to be administered to the subject is an ultra-low dose protein, wherein the low dose protein solution undergoes a further dilution step. In particular, the method of administering an ultra-low dose soluble protein comprises: (a) adding an IVSS to an isotonic aqueous solution in a first container to form a first pretreated container, (b) adding an amount from the protein stock solution to the first pretreated container to form a low dose protein solution; (c) adding an IVSS to an isotonic aqueous solution in a second container to form a second pretreated container; and (d) adding an amount of the low dose protein solution in step (b) to the second pretreated container of step (c) to form an ultra-low dose protein solution, and (e) administering the low dose protein solution of step (b) to an individual in need thereof.

This invention relates to the field of medical data-driven dose prediction technology, and discloses a method, system, device, and storage medium for individualized dose prediction of hypothyroidism based on medical data. The method includes: constructing a standardized feature vector based on the child's weight, age in days, corrected age in months, current L-T4 dose, TSH value, FT4 value, previous TSH value, TSH rate of change, feeding method, month of consultation, etiology of hypothyroidism, comorbidity status, previous dose adjustment magnitude, and age at which TSH first reached target levels; extracting TSH dynamic trajectory features from the child's TSH time-series data from previous follow-ups; obtaining a basic recommended dose using a gradient boosting decision tree model constructed with counterfactual filtering training data; and correcting the basic recommended dose to obtain an individualized recommended dose. This method improves the prediction accuracy of the gradient boosting decision tree model and allows the individualized recommended dose to simultaneously take into account multiple clinical confounding factors.

The instant application describes improved methods and compositions for the systemic delivery of therapeutic exosomes to a subject in need thereof. In certain embodiments, the current invention reduces the amount of exosomes delivered to liver, spleen and combinations thereof to allow greater distribution to other areas of the body such as, but not limited to, the brain, pancreas, lung, kidney, muscle. In certain embodiments, the methods involve the injection of one or multiple doses of non-therapeutic exosomes prior to the injection of a suitable therapeutic dose of exosomes with a therapeutic payload. Also included are methods to improve immune clearance of exosomes in subjects by inhibiting phagocytosis.

The invention provides a micro-enema preparation and quantitative evaluation method for improving the quality of a rectum magnetic resonance image, and the method comprises the steps: S2, carrying out a glycerine enema micro-enema operation, squeezing glycerine enema into the rectum, maintaining the operation for a preset time, and recording the defecation frequency and the last defecation character; s3, selecting the dosage of the microenema enema, carrying out grouped experiments by setting a plurality of doses, recording related scores, and selecting the dosage of the enema enema meeting clinical requirements; s4, selecting an on-machine time window before magnetic resonance examination after microenema, performing rectum magnetic resonance examination at a plurality of time nodes after defecation through grouping experiments, observing related scores, and selecting an on-machine time window with a good intestinal tract preparation effect; and S5, carrying out micro-enema adverse reaction evaluation, evaluating a plurality of grades of the subject, calculating an adverse reaction score according to a weighting formula, carrying out clinical decision making, and if the adverse reaction score is lower than a threshold value, terminating the operation and carrying out further processing.

The invention discloses application of a nutritional composition containing alpha-hydroxyisocaproic acid in weight management and blood fat improvement, and belongs to the fields of biological medicine manufacturing, biological medicine application and functional food development. The nutritional composition comprises alpha-hydroxyisocaproic acid and at least one second functional nutritional component, and the second functional nutritional component is preferably selected from one or more of the following components: 1) one or more of tea polyphenol and capsaicin; 2) one or more of beta-glucan, inulin and resistant dextrin; 3) one or more of medium chain triglyceride and sn-1, 3 diglyceride; under the condition of the same intake cycle and dosage, the nutritional composition can significantly improve the weight management effect and reduce related indexes of blood fat through a multi-way synergistic effect, and is combined with GLP-1 drugs or sequentially applied to weight management so as to reduce the risk of weight rise after drug withdrawal.

Compositions and principles for use before parturition in the prophylactic treatment of hypocalcemia in ruminant animals include compositions having phosphate binders for the prophylactic treatment of parturient hypocalcemia in ruminant animals. These compositions are presented in unit dosage forms, with one or more doses administered daily to the gastrointestinal tract of the ruminant animal, or in wet form. The composition contains one or more phosphate binders and one or more nutrients selected from minerals, vitamins, and amino acids, as well as a composition that includes an inhibitor of the small intestinal Na-phosphate transporter for the prophylactic treatment of parturient hypocalcemia in ruminant animals. Phosphate binders are selected from aluminum, iron, sevelamer, and lanthanum salts, with either inorganic or organic acids, hydrates thereof, or any mixture thereof.

The invention provides an application of an active ingredient targeting miR-365a-3p or a preparation product containing the active ingredient in preparation of a medicine for preventing and treating non-traumatic femoral head necrosis disease. The active ingredient is a medicine composition for dredging arthralgia and generating bone and / or beta-achyransterone. According to the application, experiments prove that the arthralgia-dredging and bone-growing soup and beta-achyranthes bidentata sterone can promote angiogenesis and osteogenesis by improving the expression of miR-365a-3p, so that the arthralgia-dredging and bone-growing soup and the beta-achyranthes bidentata sterone play a positive role in treating NONFH; on a constructed SONFH rabbit model, it is verified that the arthralgia-relieving bone-generating soup can promote bone tissue repair, inhibit fat formation and effectively adjust bone fat metabolism steady state unbalance to achieve bone fat metabolism balance; the optimal dosage of the arthralgia-dredging and bone-generating soup is explored, and it is proved that the arthralgia-dredging and bone-generating soup achieves the effect of regulating and controlling the dynamic balance of the bone fat through a multi-target-point synergistic mechanism of regulating and controlling lipid metabolism, promoting osteogenesis and improving the microenvironment.

The invention discloses an exogenous FSH decreasing injection optimization method for inducing donor cattle superovulation, and relates to the technical field of animal husbandry biological breeding. The method comprises the following steps: acquiring physiological feature data and ovarian reserve function data of donor cattle, constructing an ovarian sensitivity evaluation model and calculating an ovarian sensitivity index; mapping the ovarian sensitivity index into an elimination rate constant, and generating an accumulated blood concentration sequence and a blood concentration metabolism curve according to a superposition principle by combining an injection time point sequence, an injection dosage sequence and a pharmacokinetic parameter table; a multi-target particle swarm optimization algorithm is adopted, follicular development synchronization rate maximization and ovarian over-stimulation risk minimization serve as targets, the fitness is calculated based on a blood concentration metabolism curve, iterative optimization is conducted, and the optimal initial injection dosage and the optimal decline gradient coefficient are output; generating an optimal decline dosing scheme parameter set according to the optimal decline dosing scheme parameter set; while the follicle development consistency and superovulation output are improved, the superovulation treatment stability is improved.

Methods, systems and apparatuses for dose optimization is disclosed. A predetermined threshold may be assigned to a medication. Dose-responses from each subject of a plurality of subjects may be collected and evaluated so that a determination may be made regarding whether a particular dose is equal to a true minimum dose with satisfactory efficacy value.

The invention discloses a colon-targeted Pickering emulsion stabilized by rhein-chitosan composite nanoparticles, a preparation method and an application of the colon-targeted Pickering emulsion. Rhein-chitosan is coupled and then crosslinked with sodium tripolyphosphate to form the rhein-chitosan composite nano-particles, and the nano-particles have better hydrophobicity and acid and alkali resistance stability; the nano-particle suspension and fish oil containing rhein are homogenized and emulsified at a high speed to obtain the Pickering emulsion entrapped with the rhein, and the Pickering emulsion has relatively high rhein drug loading capacity, better stability and good colon-specific release and slow release characteristics; and the traditional Chinese medicine composition has a dose-dependent relieving effect on dextran sodium sulfate induced ulcerative colitis mice, can inhibit inflammatory response and repair intestinal barrier functions, can effectively avoid intestinal nutrition loss caused by rhein, and has a good application prospect.

This invention relates to the field of biomedical data processing technology, specifically to a stratification system for sepsis-related secondary invasive fungal infections based on laboratory data. The invention obtains the degree of static intestinal baseline damage by considering serum lactate concentrations at different historical testing times, temporal characteristics, and a preset maximum backtracking period; it obtains the cumulative dosage of antimicrobial drugs and the hourly cumulative distribution value of drug use based on the drug dosage distribution at different medication times within a neighborhood of the real-time trigger time; it obtains the overall degree of inflammation reduction and the hourly cumulative distribution value of inflammation regression based on the procalcitonin concentration distribution at testing times within a neighborhood; and it further obtains the net drug-induced intervention level. Based on the degree of static intestinal baseline damage and the net drug-induced intervention level, the fungal infection characteristics are stratified. This invention, by considering non-drug-induced interference, accurately obtains the comprehensive risk level of fungal infection, improving the effectiveness of fungal infection stratification.

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease DPP-4 activity or levels, visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for reducing or decreasing DPP-4 activity or levels in a mammal is provided where the composition comprises an effective amount of Dichrostachys glomerata provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

The present application relates to the technical field of weight loss products, and particularly relates to a nutritional composition for reducing fat and blood sugar and application thereof; the nutritional composition comprises epigallocatechin gallate, animal bifidobacterium lactis BPL1 and phyllanthus emblica extract; the mass concentration ratio of the epigallocatechin gallate, the animal bifidobacterium lactis BPL1 and the phyllanthus emblica extract is 1:0.12-485.20:5.45-87.34; the present application realizes the following breakthroughs by compounding epigallocatechin gallate (EGCG), animal bifidobacterium lactis BPL1 (BPL1) and phyllanthus emblica extract (PEL): multi-target point synergy: simultaneously regulating fat accumulation, lipid droplet dynamics and fatty acid composition, covering multiple pathological links of obesity; reducing dose-dependent risk: reducing the high concentration requirement of single component by compounding, and improving safety.

Techniques disclosed herein relate to safe correction boluses. In some embodiments, the techniques involve obtaining a plurality of sensor glucose readings for a patient. The techniques may further involve determining, based on the plurality of sensor glucose readings that the patient has consumed a meal. The techniques may further involve in response to determining the patient has consumed the meal, reducing a hypoglycemia threshold from a first value to a second value lower than the first value. The techniques may further involve determining a correction bolus dosage based on the reduced hypoglycemia threshold.

The invention discloses a nutrition evaluation and personalized nutrition intervention system for children during hospitalization, and relates to the technical field of medical health information, and the system comprises a terminal which is used for collecting daily multi-omics data, medication data and nutrition intake data of children with metabolic diseases; the monitoring equipment is used for collecting daily growth and development data of the metabolic disease children; the processor is used for outputting daily metabolic capability data and nutrient utilization rate data through a neural network according to the multi-omics data; and according to the metabolic capability data and the medication data, performing linear calculation to obtain drug absorption data. According to the scheme, by constructing the knowledge base containing the quantitative parameters and combining interval matching, function calculation and a priority weighting mechanism, the actual influence degree on the nutrients in a multi-drug scene can be accurately calculated, the problem of nutrient influence evaluation deviation caused by neglecting drug dose difference and multi-drug interaction in the prior art is solved, and the evaluation accuracy is improved. The actual influence coefficient of the medicine on various nutrients can be accurately quantified.

The invention relates to the fields of therapy and drug delivery. It is based on an unexpected finding that a combination of an oligonucleotide-based medicament with a saponin component comprising a penta-cyclic triterpene saponin of a 12,13-dehydrooleanane aglycone core, not only does not appear to be associated with oligonucleotide medicament-induced nephrotoxic effects after systemic administration in vivo, but also that it allows the oligonucleotide-based medicament to enter and act on its nucleic acid target inside of the kidney cells instead of remaining unproductively trapped in renal subcellular compartments or being eliminated into the urine via the renal glomerular filtration system. In line with this finding, herein disclosed are therapeutic combinations, compositions, and formulations, as well as methods of treatment involving their administration, which comprise an oligonucleotide-based medicament that acts on an intracellular nucleic acid target in the kidney cells and / or in the cells of the spleen, being the other blood filtering organ in addition to the kidney, and a saponin component that enables the effective release of said medicament inside of these cells, thus allowing its use at a much lower and safer dose. The provision of the presented herein therapeutic combinations enables effective modulation of gene expression in the kidney and / or spleen cells and, therefore, it opens not only new treatment options for kidney diseases, in particular those involving inflammation and / or splenomegaly, but also for diseases of other organs which affect or are affected by the pathological processes happening in the kidneys and / or in the spleen, in particular being inflammatory processes.

This invention relates to the field of computational toxicology, and in particular to a precise method for comparing the consistency of animal and non-animal toxicity evaluation results. This method acquires in vivo baseline data from animals and in vitro test data from non-animals. It employs a dynamic time warping algorithm and radial basis function kernel function to construct correction coefficients and perform equivalent mapping to generate a converted sequence. Based on a binary classification mapping of toxicity thresholds, a confusion matrix is ​​constructed to calculate sensitivity, specificity, and predicted values. Each indicator is treated as an independent source of evidence, and the Mahalanobis distance is calculated using the covariance matrix to generate a basic probability allocation function. The D-S evidence theory combination rule is applied for fusion, and a secondary factor allocation is introduced when there is conflict. Finally, the result is compared with a preset threshold to determine the feasibility of substitution. This invention adaptively eliminates the nonlinear misalignment difference between in vivo and in vitro dose responses, providing an objective quantitative judgment standard for toxicological substitution verification.

A processor-implemented method includes obtaining a measured glucose value of a person; fitting a physiological model to a portion of the measured glucose values within a window of time following the start of the meal to determine meal-specific values of parameters of the physiological model, the physiological model characterizing a glycemic response of the person to the meal; using the physiological model and meal-specific values of parameters of the physiological model to estimate the amount of residual glucose or carbohydrate of the meal that will not be counteracted by insulin that has been delivered to the person; and determining a dose of a corrected bolus to be delivered to the person based on the amount of residual glucose or residual carbohydrate of the meal.

The invention relates to a bacteriostatic feed and a preparation method and application thereof, the bacteriostatic feed comprises a basic ration and yeast essence, the content of beta-glucan in the yeast essence is 25-50%, and the relative molecular weight of more than 99% of beta-glucan is 3.0 * 10 < 5 >-1.0 * 10 < 6 >; the content of mannan in the yeast essence is greater than or equal to 20%, and the relative molecular weight of mannan of 99% or above is 8.0 * 10 < 5 >-2.0 * 10 < 6 >. The yeast essence involved in the feed disclosed by the invention is added into the feed as a single substance, the recommended dosage is stable, and the yeast essence shows a relatively good resistance replacement effect in in-vitro inhibition zone simulation and in-vivo test verification of bred animals; a set of efficient and feasible antibiotic substitution scheme can be provided for the animal breeding industry, meanwhile, the defects of antibiotic drug resistance and residues and poor effect and poor stability of current antibiotic substitution products are overcome, and the future prospect is considerable.

The invention discloses a method for in-vitro broad-spectrum stimulation of immune checkpoint up-regulation and application, the method comprises the following steps: placing a Jurkat cell line in an RPMI-1640 culture medium containing 10% of fetal calf serum and 1% of penicillin-streptomycin, carrying out in-vitro stimulation for 24-72 hours by adopting PHA with a concentration of 0.1-5 [mu] g / mL under the conditions of 37 DEG C and 5% of CO2, activating NF-kB and / or MAPK signal channels, and carrying out in-vitro broad-spectrum stimulation of immune checkpoint up-regulation. The broad-spectrum up-regulation of co-stimulatory immune checkpoints of CD28, CD40L, ICOS and the like and co-inhibitory immune checkpoints of PD-1, LAG-3, CTLA-4 and the like is realized, and the high expression state can be maintained for at least 72 hours after the PHA is removed. The invention also discloses the in-vitro broad-spectrum immune checkpoint positive T cell model constructed by the method, and the up-regulation of immune checkpoints in the model is accompanied by the increase of dose-dependent secretion of various cytokines. The model can replace a traditional model, is applied to toxicology and pharmacology research of immune checkpoint antagonists and combined synergistic effect and immune checkpoint regulation and control mechanism research, is simple and convenient to operate and high in repeatability, and provides an efficient tool for research and development of related drugs.

The present invention provides a formulation comprising a blend of probiotics and fibers for weight management, digestive health management, and health parameter management in a subject The formulation aids in weight loss particularly in overweight subjects, while concurrently improving health parameters. Also provided are dosage forms, dosages, and kits comprising said formulation and methods and modes of administration of the formulation.